Cupovic, Jovana
Ring, Sandra S.
Onder, Lucas
Colston, Julia M. http://orcid.org/0000-0002-3337-2455
Lütge, Mechthild http://orcid.org/0000-0001-9011-5319
Cheng, Hung-Wei
De Martin, Angelina
Provine, Nicholas M. http://orcid.org/0000-0002-9694-2216
Flatz, Lukas
Oxenius, Annette http://orcid.org/0000-0002-2079-2354
Scandella, Elke
Krebs, Philippe http://orcid.org/0000-0003-4918-6654
Engeler, Daniel http://orcid.org/0000-0003-1383-4701
Klenerman, Paul http://orcid.org/0000-0003-4307-9161
Ludewig, Burkhard http://orcid.org/0000-0002-7685-573X
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (159188, 166500)
Wellcome Trust (099897/Z/12/A, 109965MA)
Verein fur Krebsforschung (KFS-4162-02-2017-R)
Article History
Received: 1 October 2020
Accepted: 7 June 2021
First Online: 15 July 2021
Competing interests
: L.F. is a cofounder and shareholder of Hookipa Pharma. B.L., L.O. and H.-W.C. are cofounders and shareholders of Stromal Therapeutics. S.S.R. and H.-W.C. are part-time employees of Stromal Therapeutics. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.